News Digging > Editor's Picks > Japan Approves Lynparza, Abiraterone for BRCA-Mutated Prostate Cancer
Japan Approves Lynparza, Abiraterone for BRCA-Mutated Prostate Cancer
Japan Approves Lynparza, Abiraterone for BRCA-Mutated Prostate Cancer,AstraZeneca and MSD's Lynparza (olaparib) in combination with abiraterone and prednisolone has been approved in Japan for the treatment of adult

Japan Approves Lynparza, Abiraterone for BRCA-Mutated Prostate Cancer

AstraZeneca and MSD's Lynparza (olaparib) in combination with abiraterone and prednisolone has been approved in Japan for the treatment of adult